Clinical Trials at Retina Associates of Utah

At Retina Associates of Utah, we are committed to make available the highest quality, cutting-edge treatments for patients. We participate with other major research institutions in clinical trials which provide promising investigational treatments that otherwise are not accessible to our current patient population. Study areas of interest currently include treatments for Wet Macular Degeneration, Dry Macular Degeneration, Diabetic Retinopathy, Uveitis, and Vitreomacular Traction. A brief description of our participation in each trial is given below. If any referring doctors have patients who are interested in considering participation in one of these clinical trials, please call our Research Team at 801-312-2070 for more information.

Current Trials:

Wet Macular Degeneration Trials

**LADDER** – Sponsor: Genentech
A Phase II, multicenter, randomized, active treatment – controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with subfoveal neovascular - Age-Related Macular Degeneration.

Diabetic Retinopathy Trials

**DRCR Protocol TX** – Sponsor: Diabetic Retinopathy Clinical Research Network
Protocol TX, A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema Extension Study (Protocol T Extension) returns Protocol T patients to complete one five-year visit that will provide information on treatment course, changes in visual acuity and macular edema after protocol-specific treatment was stopped.

Upcoming Trials Starting Late Summer 2018:

Wet Macular Degeneration Trials

**Panda** – Sponsor: Chengdu Kanghong Biotechnology Co, Ltd.
A Multicenter, Double-Masked, Randomized, Dose-Ranging trial to evaluate the efficacy and safety of Conbercept intravitreal injection in subjects with neovascular Age-Related Macular Degeneration.

**Ladder GR40548** – Sponsor: F. Hoffman – La Roche
A Phase III, multicenter, randomized, active treatment – Controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with subfoveal neovascular - Age-Related Macular Degeneration.
Diabetic Retinopathy Trials

Yosemite GR40349 – Sponsor: F. Hoffman – La Roche
A Phase III, multicenter, randomized, double- masked, active comparator – controlled study to evaluate the efficacy and safety of R06867461 in patients with Diabetic Macular Edema.

Completed Trials:

Wet Macular Degeneration Trials

HAWK – Sponsor: Alcon
A study to compare the efficacy and safety of a new long acting investigational medication (RTH258) given every three (3) months to the current standard of care medication EYLEA given every two (2) months in patients with treatment-naïve Wet Macular Degeneration.

CEDAR – Sponsor: Allergan
A study to compare the efficacy and safety of a new long acting investigational medication (ABICIPAR) given either every two to three (2 or 3) months to the current standard of care medication Lucentis given monthly in patients with treatment-naïve Wet Macular Degeneration.

STAIRWAY – Sponsor: F. Hoffmann-La Roche Ltd
A 52-week study to investigate the efficacy, safety, and pharmacokinetics of RO6867461 administered at 12- and 16-week intervals in treatment-naïve patient with nAMD.

AVENUE – Sponsor: F. Hoffmann-La Roche Ltd
A 36 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with choroidal neovascularization secondary to Age-Related Macular Degeneration.

Dry Macular Degeneration Trial

CHROMA – Sponsor: F. Hoffmann-La Roche Ltd
A study to assess the efficacy and safety of intravitreal injections of Lampalizumab (an anti-complement factor D antibody fragment) for geographic atrophy secondary to Dry Age-Related Macular Degeneration.

OMASPECT – Sponsor: F. Hoffmann-La Roche Ltd
An open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have complete a Roche-sponsored study.

CLG561/LFG316 – Sponsor: Alcon
A randomized, multi-center, single masked, sham controlled, proof – of – concept study of intravitreal CLG561 as a monotherapy and in combination with LFG316 in subjects with geographic atrophy.
**Diabetic Retinopathy Trials**

**DRCR Protocol T** – Sponsor: Diabetic Retinopathy Clinical Research Network
A study comparing the relative safety and efficacy of avastin versus Lucentis versus EYLEA in patients with Diabetic Macular Edema.

**DRCR Protocol V** – Sponsor: Diabetic Retinopathy Clinical Research Network
A study to compare the safety and efficacy of prompt laser + deferred anti-VEGF (EYLEA) vs. prompt anti-VEGF alone vs. observation + deferred anti-VEGF in eyes with center-involved Diabetic Macular Edema and good vision (20/25 or better).

**DRCR Protocol U** – Sponsor: Diabetic Retinopathy Clinical Research Network

**PANORAMA** – Sponsor: Regeneron Pharmaceuticals
Description: A Phase III, double-masked, randomized study of the efficacy and safety of intravitreal Aflibercept injection in patients with moderately severe to severe non-proliferative diabetic retinopathy.

**Uveitis Trials**

**SAKURA** – Sponsor: Santen
A study to evaluate the efficacy and safety of intravitreal sirolimus (an immunosuppressive agent) for the treatment of active posterior uveitis.

**EYEGUARD A** – Sponsor: XOMA
A study to assess the efficacy and safety of subcutaneous Gevokizumab (anti-Interleukin-1β antibody) alone for the treatment of active posterior or pan-uveitis.

**EYEGUARD C** – Sponsor: XOMA
A study to assess the efficacy and safety of subcutaneous Gevokizumab (anti-Interleukin-1β antibody) for the treatment of active intermediate, posterior or pan-uveitis controlled with systemic treatment.

**EYEGUARD E** – Sponsor: XOMA
An extension study of Eyeguard A or C patients.

**Vitreomacular Traction Trial**

**ORBIT** – Sponsor: ThromboGenics
A study to observe outcomes and safety of JETREA for Vitreomacular Traction in real world standard of care practice.